Cdk2 Inhibitor II

Cdk2 Inhibitor II (CAS No.: 222035-13-4) is a potent, selective, and cell-permeable small-molecule inhibitor of cyclin-dependent kinase 2 (CDK2), a key serine/threonine kinase that associates with cyclins A and E to regulate S phase progression and the G2–M transition of the cell cycle. This compound functions as a reversible, ATP-competitive inhibitor, effectively blocking CDK2 kinase activity with reported potency in the nanomolar range, thereby modulating downstream signaling pathways involved in cell cycle control and cellular proliferation. By targeting CDK2, Cdk2 Inhibitor II serves as a valuable molecular probe for dissecting the role of CDK2 in oncogenic processes, including uncontrolled cell division and tumorigenesis, and for evaluating CDK2 as a therapeutic target in cancer and other proliferative disorders. It is widely utilized in biochemical assays and cellular models to study cell cycle dynamics, signal transduction, and drug sensitivity, with experimental concentrations typically optimized according to specific assay conditions and research objectives in both in vitro and in vivo systems.